During the past decade, University of Alabama at Birmingham, IDS Pharmacy conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 5 clinical trials were completed, i.e. on average, 166.7% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 2 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Alabama at Birmingham, IDS Pharmacy" #1 collaborator was "Astellas Pharma Inc" with 2 trials as a collaborator, "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 2 trials as a collaborator and "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "University of Alabama at Birmingham, IDS Pharmacy" are "Prostate Cancer" (2 trials), "ALK-positive Advanced NSCLC" (1 trials), "Breast Cancer Metastatic" (1 trials), "Cancer of the Prostate" (1 trials) and "Colitis, Ulcerative" (1 trials). Many other conditions were trialed in "University of Alabama at Birmingham, IDS Pharmacy" in a lesser frequency.

Most popular intervention types in "University of Alabama at Birmingham, IDS Pharmacy" are "Drug" (6 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Enzalutamide" (2 trials), "Placebo" (2 trials), "Anrukinzumab" (1 trials), "Bicalutamide" (1 trials) and "Crizotinib" (1 trials). Other intervention names were less common.

The vast majority of trials in "University of Alabama at Birmingham, IDS Pharmacy" are 3 trials for "All" genders, 2 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "University of Alabama at Birmingham, IDS Pharmacy". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in University of Alabama at Birmingham, IDS Pharmacy, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in University of Alabama at Birmingham, IDS Pharmacy, 2 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".